Yes danhoff, I agree , no mention of FebriDx. In my view this is the only product with real potential for AT1. we at least manufacture and
supply the test assembly.
With the Ag tests, we are simply a re-seller among many, and I believe Covid will pass within the next 12-18months, even Fauci believes it
will be under control by the northern summer of 2022.
Really don't believe the HIV market is that big, or big enough.( Thankfully).
AT1 has been in the HIV space for years, and sales are still slim.
Therefore, continual growth of FebriDx and hopeful FDA approval are the keys for AT1 growth.
Ann: Quarterly Activity Report - 30 September 2021, page-9
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.1¢ |
Change
-0.001(3.13%) |
Mkt cap ! $19.81M | |||
| Open | High | Low | Value | Volume |
| 3.2¢ | 3.2¢ | 3.0¢ | $49.69K | 1.588M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38735 | 3.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.2¢ | 418145 | 4 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
3.1¢ |
Change
-0.001 ( 3.13 %) |
||||
| Open | High | Low | Volume | ||
| 3.1¢ | 3.2¢ | 3.0¢ | 536671 | ||
| Last updated 15.58pm 17/05/2024 ? | |||||
| AT1 (ASX) Chart |